Clinical trials on Chronic Hepatitis B

Understanding Chronic Hepatitis B

Chronic Hepatitis B is a long-lasting infection of the liver caused by the hepatitis B virus (HBV). This condition can lead to severe liver complications, including liver cirrhosis, liver failure, and liver cancer. Unlike its acute counterpart, chronic hepatitis B persists beyond six months, indicating the body’s inability to clear the virus. The risk of chronic infection is higher in individuals infected at a young age, particularly newborns and children under five years of age, where the risk can exceed 90%.

Transmission and Risk Factors

The hepatitis B virus spreads through contact with infected bodily fluids, such as blood, semen, and vaginal secretions. Common modes of transmission include mother-to-child transmission at birth, unprotected sexual contact, sharing needles or syringes, and transfusions of unscreened blood products. Individuals at increased risk include healthcare workers, people with multiple sexual partners, intravenous drug users, and those living in close contact with someone infected with HBV.

Prevention and Management

  • Vaccination: The most effective way to prevent hepatitis B is through vaccination, which is available for both adults and children.
  • Screening and Blood Safety: Regular screening for individuals at high risk and ensuring the safety of blood products can prevent transmission.
  • Antiviral Medications: While there is no cure for chronic hepatitis B, antiviral medications can significantly reduce the risk of liver disease and prevent transmission to others.

Early diagnosis and regular monitoring are crucial in managing chronic hepatitis B and mitigating its long-term impacts on liver health. With appropriate care, individuals with chronic hepatitis B can lead long, healthy lives.

Prognosis for Chronic Hepatitis B

Chronic Hepatitis B is a long-term viral infection of the liver that can lead to serious health issues. The prognosis for Chronic Hepatitis B varies widely among individuals and is influenced by factors such as age at infection, gender, genetic factors, and co-existing medical conditions. It is observed that many individuals with Chronic Hepatitis B lead long, healthy lives without significant liver damage. However, there is a subset of patients who may develop progressive liver disease, including cirrhosis and liver cancer, over decades. Regular monitoring and lifestyle adjustments are crucial in managing the disease’s progression. The long-term outlook tends to be better for those who are diagnosed early and monitored regularly, as this allows for timely medical interventions if necessary. It is important to note that, with current medical advancements, the life expectancy for individuals with Chronic Hepatitis B can be close to that of the general population, provided that appropriate medical care is received.

Complications in Chronic Hepatitis B

Chronic Hepatitis B can lead to serious health issues over time. One of the most concerning complications is liver scarring, known as cirrhosis. This condition can cause the liver to struggle with filtering toxins, potentially leading to fatigue, easy bruising, and jaundice, where the skin and eyes turn yellow. In severe cases, cirrhosis can result in liver failure, a life-threatening situation where the liver can no longer function properly.

Another possible complication is liver cancer, which may develop without any early symptoms, making it harder to detect and manage. Chronic Hepatitis B can also cause blood vessel problems, such as aneurysms, which are abnormal bulges in blood vessels that can burst and lead to dangerous bleeding.

These complications can significantly impact daily life, causing physical discomfort, limiting activity levels, and affecting emotional well-being. Monitoring health closely is important to manage these risks in cases of Chronic Hepatitis B.

Treatment Methods for Chronic Hepatitis B

For the management of Chronic Hepatitis B, several non-clinical trial alternatives are recommended. Dietary adjustments, such as the reduction of alcohol intake and the consumption of a balanced diet rich in fruits, vegetables, and lean proteins, support liver health. Regular physical activity, including moderate-intensity exercises like walking or swimming, can improve overall well-being.

Pharmacotherapy options, which should be discussed with healthcare providers, may include antiviral medications to help control the virus and maintain liver function. These medications are tailored to individual needs and are monitored for effectiveness and side effects.

Modern technology offers tools for monitoring liver health, such as mobile apps that track medication schedules and lifestyle changes. Wearable devices can also encourage physical activity and provide data on personal health metrics.

The incorporation of these methods can contribute to the management of Chronic Hepatitis B, complementing medical advice and treatment plans. It is always recommended to consult healthcare professionals before making any significant changes to treatment or lifestyle.

  • CT-EU-00053518

    Testing Tenofovir Alafenamide for children and teens with Chronic Hepatitis B

    This research study is examining a drug called Tenofovir Alafenamide (TAF) for kids and teens who have chronic hepatitis B virus infection. The study will compare TAF to a placebo. The purpose is to learn if TAF is safe, tolerated well, and more effective for treating chronic hepatitis B in young people. The amounts of TAF will be checked in the body at different times after taking the drug. Also, the participants will be asked about the taste of the medicine and if it was easy to swallow.

    • Tenofovir alafenamide
  • Testing new medicine for safe treating Chronic Hepatitis B

    This study is about a new drug called IMC-I109V which is meant to help people who have a condition called Chronic Hepatitis B, a long-lasting infection in the liver. The researchers want to see if the new drug is safe, and if it can help to fight off the virus. This is the first time that people will be given this drug, hence why this study is so important. The trial involves different doses of the drug to see which works best and is safest. The researchers will check patient’s vital signs and run lab tests for safety measures.

    • IMC-I109V-101
  • Safety and efficacy of new therapy for chronic Hepatitis B

    The study evaluates GSK3965193 across four parts to assess safety and effectiveness. Initially, the drug is tested in healthy individuals (Parts 1 and 2) to observe bodily reactions and safety. Next, its potential to reduce Hepatitis B virus levels is examined in patients with chronic Hepatitis B (Part 3). The final phase (Part 4) explores the combined effect of GSK3965193 with bepirovirsen, another medication, to enhance its impact against the virus.

    • GSK3965193- new potential medication for hepatitis B
    • Bepirovirsen
  • New drug trial for long-term control of hepatitis B

    This study focuses on the long-term effects of GSK3228836 in patients with hepatitis B. It assesses the durability of the drug’s effectiveness, specifically how long patients maintain a sustained virological response (SVR) after treatment. The study will involve two groups: people who have not previously used Nucleos(t)ide (NA) analogue therapy and people controlled by NA therapy. Participants will be monitored for re-emergence of the hepatitis B virus and the need for additional treatment. The study aims to gain insight into the long-term effectiveness of GSK3228836 in the treatment of hepatitis B virus infection.

    • bepirovirsen 
  • Bepirovirsen: a new treatment approach for chronic Hepatitis B

    This study is looking at a medicine called Bepirovirsen for people with chronic hepatitis B who are already taking another medicine known as ‘NA’. The study, called “B-Well 2”, will consist of four parts. Firstly, all patients will receive Bepirovirsen or a product without the medicine called a placebo for six months. In the next part, all patients will continue taking “NA” medications for another six months. Some patients will then be asked to stop taking “NA” while others will continue taking it for an additional six months. In the final part, doctors will look at patients who have stopped using “NA” for the next six months. The idea is to see if Bepirovirsen can help control the hepatitis B virus long term, even after all treatments have been stopped.

    • Bepirovirsen
  • Bepirovirsen treatment for chronic hepatitis B

    This study investigates the effectiveness and safety of a new treatment, bepirovirsen, for chronic Hepatitis B in patients already taking specific antiviral drugs. Participants will be divided into groups, receiving either bepirovirsen or a placebo, followed by their usual antiviral medication. The study consists of four stages, including initial treatment, continued antiviral therapy, a phase where some may stop their antiviral drugs, and a final follow-up. The goal is to see if bepirovirsen can improve Hepatitis B outcomes compared to standard treatment alone. The study will take place over approximately 104 weeks, with eligibility criteria ensuring participants have chronic Hepatitis B and are on stable antiviral therapy.

    • Bepirovirsen